...
首页> 外文期刊>Scientific reports. >Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease
【24h】

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease

机译:非酒精性脂肪肝病中的脱脂性和纤维化检测的成像生物标志物

获取原文
   

获取外文期刊封面封底 >>

       

摘要

There is a need, in NAFLD management, to develop non-invasive methods to detect steatohepatitis (NASH) and to predict advanced fibrosis stages. We evaluated a tool based on optical analysis of liver magnetic resonance images (MRI) as biomarkers for NASH and fibrosis detection by investigating patients with biopsy-proven NAFLD who underwent magnetic resonance (MR) protocols using 1.5T General Electric (GE) or Philips devices. Two imaging biomarkers (NASHMRI and FibroMRI) were developed, standardised and validated using area under the receiver operating characteristic curve (AUROC) analysis. The results indicated NASHMRI diagnostic accuracy for steatohepatitis detection was 0.83 (95% CI: 0.73-0.93) and FibroMRI diagnostic accuracy for significant fibrosis determination was 0.85 (95% CI: 0.77-0.94). These findings were independent of the MR system used. We conclude that optical analysis of MRI has high potential to define non-invasive imaging biomarkers for the detection of steatohepatitis (NASHMRI) and the prediction of significant fibrosis (FibroMRI) in NAFLD patients.
机译:在NAFLD管理中有需要开发非侵入性方法来检测脂肪疏皮性(纳什)并预测先进的纤维化阶段。我们评估了一种基于肝脏磁共振图像(MRI)的光学分析的工具,作为使用1.5T通用电气(GE)或飞利浦设备的磁共振(MR)协议的活检证实NAFLD患者进行肿瘤和纤维化检测的生物标志物。在接收器操作特性曲线(AUROC)分析下,使用面积标准化和验证了两种成像生物标志物(NASHMRI和FIBROMRI)。结果表明,肉瘟病检测的纳什马里诊断精度为0.83(95%CI:0.73-0.93),纤维纤维诊断准确性为大量纤维化测定为0.85(95%CI:0.77-0.94)。这些发现与使用的MR系统无关。我们得出结论,MRI的光学分析具有很高的潜力,以定义用于检测STEATOHPATISIS(NASHMRI)的非侵入性成像生物标志物以及NAFLD患者的显着纤维化(FIBROMRI)的预测。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号